Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

BIO Commends Senate Committee On Small Business And Entrepreneurship's SBIR Reauthorization
Under legislation reported by the Senate Committee on Small Business and Entrepreneurship, small companies that receive the majority of their financing from venture capital will once again be considered eligible to compete for Small Business Innovation Research (SBIR) grants. The change will allow more small biotechnology start-ups to compete for these funds and continue critical research and development of medical advancements and breakthroughs. Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood made the following statement today:

Abbott Launches New Instrument To Complete Family Of ARCHITECT Immunochemistry Analyzers
Today at the American Association for Clinical Chemistry"s Clinical Lab Expo in Chicago, Abbott (NYSE: ABT) announced the launch of a new diagnostic instrument - the ARCHITECT® c4000® clinical chemistry analyzer which performs diagnostic tests that monitor general health including a patient"s levels of sodium, potassium, chloride and organ function.
News of the day
Twin Study Examines Associations Between Depression And Coronary Artery Disease
Major depression and coronary artery disease are only modestly related throughout an individual"s lifetime, but studying how the two interact over time and in twin pairs paints a more complex picture of the associations between the conditions, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals. For example, the association between coronary artery disease onset and major depression risk is much stronger over time than vice versa.
Endocrinology

Bovie Medical Corporation Announces 510K Submission To The FDA For Its BOSS Soft Tissue Coagulation Device

Bovie Medical Corporation (the "Company") (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, announced a 510K submission to the FDA seeking pre-market clearance for Bovie"s BOSS for surgical applications where soft tissue bipolar coagulation is desired. The BOSS is the latest generation device based on Bovie"s saline enhanced sintered steel technology. The BOSS delivers RF energy simultaneously with saline to perform coagulation of soft tissue and bone, with minimal smoke, charring and sticking of tissue as well as reduced blood loss. Saline enhanced surgeries reduce operating time while improving post-operative outcomes and shortens recovery time. The BOSS will primarily be targeted towards orthopedic hip and knee reconstruction surgeries, which are significant markets, with over 1.3 million procedures performed in the United States annually. These procedures represent large and growing markets due to a more active and aging population. The worldwide market is expected to exceed $500 million in 2009. Andrew Makrides, president of Bovie, stated, "In today"s economic environment, where controlling medical costs is important, the BOSS technology meets the needs of patients, surgeons and hospitals. Reduced blood loss, shortened operating and recovery time makes the BOSS a technology product that targets a large and growing market." For further information about the Company"s current and new products, please refer to the Investor Relations section of Bovie"s website http://www.boviemedical.com. Bovie Medical Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009